SEARCH OUR PAGES

OSE-172

OSE-172

In recent years, immunotherapies have driven significant clinical progress and increased hopes for patients suffering from various types of cancer.

Of note, the tumor microenvironment (TME), in particular the presence and immune-status of tumor-associated macrophages (TAM) as well as myeloid and dendritic cells, has been closely linked to tumor activity and responsiveness to T-cell-targeted immunotherapies.

OSE’s R&D team has taken interest in this critical aspect of the TME, focusing on the SIRPα / CD47 pathway which controls the activation of macrophages and dendritic cells.

OSE-172, a SIRPα an antagonist and first-in-class myeloid checkpoint inhibitor in this area, selectively inhibits SIRPα thus restoring TAM and dendritic cells’ activity in response to tumors:

Pre-clinical studies have demonstrated OSE-172’s ability within the TME to inhibit pro-tumorigenic cells while activating anti-tumorigenic ones, generating high interest for this innovative breakthrough approach.

OSE Immunotherapeutics is actively working on several new approaches focused on modulating the tumor microenvironment.

ABOUT THE OSE-172 CLINICAL PROGRAM

In April 2018, OSE signed a worldwide license and collaboration agreement with Boehringer Ingelheim to develop OSE-172 in multiple cancer indications. OSE-172 is planned to enter clinical phase in Q1 2019.